Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ganz

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Journal of Medical Economics|June 24, 2021
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113Michael Serbin, Charles Yonan, Michael L Ganz
Ophthalmology|September 12, 2006
Prevalence and correlates of children's diagnosed eye and vision conditionsMichael L Ganz, Ziming Xuan, David G Hunter
Vision Research|December 1, 1973
Spatial frequency phase effects in human visionC F Stromeyer, A F Lange, L Ganz
Hospital Practice (Office Ed.)|May 15, 1985
A healthy infant with facial swelling, feverJ O Kaltman, M L Ganz, S Waskerwitz
Brain Research|September 29, 1972
The nature of perceptual deficits in visually deprived catsL Ganz, H V Hirsch, S B Tieman
Journal of Personality and Social Psychology|August 1, 1974
Interaction of locus of control and type of performance feedback; considerations of external validityR M Baron, G Cowan, R L Ganz, et al.
American Journal of Public Health|August 14, 1998
Region of birth and black diets: the Harlem Household SurveyM R Greenberg, D Schneider, M E Northridge, et al.
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Journal of Medical Economics|January 4, 2021
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesiaMichael L Ganz, Ameya Chavan, Rahul Dhanda, et al.
Journal of Medical Economics|December 23, 2014
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritisMichael L Ganz, Brian Bekker Hansen, Xavier Valencia, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Journal of Medical Economics|June 24, 2021
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113Michael Serbin, Charles Yonan, Michael L Ganz
Ophthalmology|September 12, 2006
Prevalence and correlates of children's diagnosed eye and vision conditionsMichael L Ganz, Ziming Xuan, David G Hunter
Vision Research|December 1, 1973
Spatial frequency phase effects in human visionC F Stromeyer, A F Lange, L Ganz
Hospital Practice (Office Ed.)|May 15, 1985
A healthy infant with facial swelling, feverJ O Kaltman, M L Ganz, S Waskerwitz
Brain Research|September 29, 1972
The nature of perceptual deficits in visually deprived catsL Ganz, H V Hirsch, S B Tieman
Journal of Personality and Social Psychology|August 1, 1974
Interaction of locus of control and type of performance feedback; considerations of external validityR M Baron, G Cowan, R L Ganz, et al.
American Journal of Public Health|August 14, 1998
Region of birth and black diets: the Harlem Household SurveyM R Greenberg, D Schneider, M E Northridge, et al.
Advances in Therapy|March 10, 2023
Healthcare Service Use Patterns Among Patients with Acid Sphingomyelinase Deficiency Type B: A Retrospective US Claims AnalysisRuth Pulikottil-Jacob, Michael L Ganz, Marie Fournier, et al.
Journal of Medical Economics|January 4, 2021
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesiaMichael L Ganz, Ameya Chavan, Rahul Dhanda, et al.
Journal of Medical Economics|December 23, 2014
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritisMichael L Ganz, Brian Bekker Hansen, Xavier Valencia, et al.
Pageof 9